taxifolin has been researched along with masoprocol in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (20.00) | 18.2507 |
2000's | 3 (60.00) | 29.6817 |
2010's | 1 (20.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Habtemariam, S | 1 |
Gestwicki, JE; Reinke, AA; Seh, HY | 1 |
Cabrita, EJ; Fernandes, E; Freitas, M; Marques, MM; Porto, G; Ribeiro, D; Silva, AM; Tomé, SM | 1 |
Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J | 1 |
5 other study(ies) available for taxifolin and masoprocol
Article | Year |
---|---|
Flavonoids as inhibitors or enhancers of the cytotoxicity of tumor necrosis factor-alpha in L-929 tumor cells.
Topics: Animals; Apoptosis; Drug Synergism; Flavonoids; Mice; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1997 |
A chemical screening approach reveals that indole fluorescence is quenched by pre-fibrillar but not fibrillar amyloid-beta.
Topics: Amyloid beta-Peptides; Benzothiazoles; Coloring Agents; Congo Red; Fluorescent Dyes; Indoles; Spectrometry, Fluorescence; Thiazoles | 2009 |
Inhibition of LOX by flavonoids: a structure-activity relationship study.
Topics: Dose-Response Relationship, Drug; Flavonoids; Glycine max; Humans; Leukotriene B4; Lipoxygenase; Molecular Structure; Neutrophils; Structure-Activity Relationship | 2014 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection | 2009 |